TY - JOUR
T1 - Methods for living guidelines: early guidance based on practical experience
T2 - Paper 1: Introduction
AU - Cheyne, Saskia
AU - Fraile Navarro, David
AU - Hill, Kelvin
AU - McDonald, Steve
AU - Tunnicliffe, David
AU - White, Heath
AU - Whittle, Samuel
AU - Karpusheff, Justine
AU - Mustafa, Reem
AU - Morgan, Rebecca L.
AU - Sultan, Shahnaz
AU - Turner, Tari
AU - on behalf of the Australian Living Evidence Consortium Methods and Processes Working Group and Collaborators
N1 - Funding Information:
Funding: The National COVID-19 Clinical Evidence Taskforce is supported by: Australian Government Department of Health, Victorian Government Department of Health and Human Services, The Ian Potter Foundation, Walter Cottman Endowment Fund (managed by Equity Trustees), and Lord Mayors' Charitable Foundation. The Australian Evidence-Based Clinical Guidelines for Diabetes is supported by: Australian Diabetes Society, Diabetes Australia, Australian Diabetes Educators Association, Australasian Pediatric Endocrine Group, and the Australian Government Department of Health. The Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis is supported by the Australian Government's Value in prescribing program grant, managed by the Targeted Therapies Alliance, a consortium coordinated by NPS MedicineWise. NICE receives funding from the Department of Health and Social Care in England. Work to complete the SRs which informed the IDSA COVID-19 guidelines was primary funded by the IDSA with contribution from the Evidence Foundation.
Funding Information:
We would like to acknowledge all members of the Australian Living Evidence Consortium Methods and Processes Working Group: Jodie Avery, Amanda K. Buttery, Saskia Cheyne, David Fraile Navarro, Vanessa Glennon, Kelvin Hill, Martin Howell, Renea Johnston, Steve McDonald, Melissa Murano, Liesl Nicol, Denise O'Connor, Anneliese Synnot, David Tunnicliffe, Tari Turner, Joshua Vogel, Heath White, Samuel Whittle. We would also like to acknowledge all members of the Executive: Rachelle Buchbinder, Jonathan Craig, Julian Elliott, Sally Green, Sharon McGowan, Julie Anne Mitchell, Rhiannon Tate, Tari Turner, Sophia Zoungas. We would also like to acknowledge the NICE COVID-19 Team: Fiona Glen, Anneka Patel, Emma McFarlane, Steve Sharp, Gareth Franklin, Zoe Charles, Mariam Sood, Olivia Crane, Sarah Boyce, Rachel Archer, Omnia Bilal, Aedin McSloy, Kerin Bayliss, Toby Mercer, Debra Hunter, Danielle Conroy, Ella Fitzpatrick, Kyrena Al-sboui, Harriet Wilson and Jenny Rattenbury. We would also like to acknowledge the IDSA COVID-19 guidelines team. Treatment and Management Guideline Panel: Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, Valery Lavergne, Lindsey Baden, Vincent Chi-Chung Cheng, Kathryn M. Edwards, Rajesh Gandhi, Jason Gallagher, William J. Muller, John C. O'Horo, Shmuel Shoham, M. Hassan Murad, Reem A. Mustafa, Shahnaz Sultan, Yngve Falck-Ytter. Infection Prevention Guideline Panel: John B. Lynch, Perica Davitkov, Deverick J. Anderson, Adarsh Bhimraj, Vincent Chi-Chung Cheng, Judith Guzman-Cottrill, Jasmine Dhindsa, Abhijit Duggal, Mamta K. Jain, Grace M. Lee, Stephen Y. Liang, Allison McGeer, Jamie Varghese, Valéry Lavergne, M. Hassan Murad, Reem A. Mustafa, Shahnaz Sultan, Yngve Falck-Ytter, Rebecca L. Morgan. Diagnosis Guideline Panel: Kimberly E. Hanson, Angela M. Caliendo, Cesar A. Arias, Mary K. Hayden, Janet A. Englund, Mark J. Lee, Mark Loeb, Robin Patel, Abdallah El Alayli, Osama Altayar, Payal Patel, Yngve Falck-Ytter, Valéry Lavergne, Rebecca L. Morgan, M. Hassan Murad, Shahnaz Sultan, Adarsh Bhimraj, Reem A. Mustafa. Funding: The National COVID-19 Clinical Evidence Taskforce is supported by: Australian Government Department of Health, Victorian Government Department of Health and Human Services, The Ian Potter Foundation, Walter Cottman Endowment Fund (managed by Equity Trustees), and Lord Mayors' Charitable Foundation. The Australian Evidence-Based Clinical Guidelines for Diabetes is supported by: Australian Diabetes Society, Diabetes Australia, Australian Diabetes Educators Association, Australasian Pediatric Endocrine Group, and the Australian Government Department of Health. The Australian Living Guideline for the Pharmacological Management of Inflammatory Arthritis is supported by the Australian Government's Value in prescribing program grant, managed by the Targeted Therapies Alliance, a consortium coordinated by NPS MedicineWise. NICE receives funding from the Department of Health and Social Care in England. Work to complete the SRs which informed the IDSA COVID-19 guidelines was primary funded by the IDSA with contribution from the Evidence Foundation. Declaration of interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Publisher Copyright:
© 2023 Elsevier Inc.
PY - 2023/3
Y1 - 2023/3
N2 - Objectives: To introduce methods for living guidelines based on practical experiences by the Australian Living Evidence Consortium (ALEC), the National Institute of Health and Care Excellence (NICE), and the Infectious Diseases Society of America (IDSA), with methodological support from the US Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Network. Study Design and Setting: Members of ALEC, NICE, and the US GRADE Network, convened a working group to share experiences of the methods used to develop living guidelines and outline the key differences between traditional and living guidelines methods. Results: The guidance includes the following steps: 1) deciding if the guideline is a priority for a living approach, 2) preparing for living guideline development, 3) literature surveillance and frequency of searching, 4) assessment and synthesis of the evidence, 5) publication and dissemination, and 6) transitioning recommendations out of living mode. Conclusion: This paper introduces methods for living guidelines and provides examples of the similarities and differences in approach across multiple organizations conducting living guidelines. It also introduces a series of papers exploring methods for living guidelines based on our practical experiences, including consumer involvement, selecting and prioritizing questions, search decisions, and methods decisions.
AB - Objectives: To introduce methods for living guidelines based on practical experiences by the Australian Living Evidence Consortium (ALEC), the National Institute of Health and Care Excellence (NICE), and the Infectious Diseases Society of America (IDSA), with methodological support from the US Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Network. Study Design and Setting: Members of ALEC, NICE, and the US GRADE Network, convened a working group to share experiences of the methods used to develop living guidelines and outline the key differences between traditional and living guidelines methods. Results: The guidance includes the following steps: 1) deciding if the guideline is a priority for a living approach, 2) preparing for living guideline development, 3) literature surveillance and frequency of searching, 4) assessment and synthesis of the evidence, 5) publication and dissemination, and 6) transitioning recommendations out of living mode. Conclusion: This paper introduces methods for living guidelines and provides examples of the similarities and differences in approach across multiple organizations conducting living guidelines. It also introduces a series of papers exploring methods for living guidelines based on our practical experiences, including consumer involvement, selecting and prioritizing questions, search decisions, and methods decisions.
KW - Clinical practice guidelines
KW - COVID-19
KW - Decision-making
KW - Guidelines
KW - Living evidence
KW - Methods
UR - https://www.scopus.com/pages/publications/85149863643
U2 - 10.1016/j.jclinepi.2022.12.024
DO - 10.1016/j.jclinepi.2022.12.024
M3 - Article
AN - SCOPUS:85149863643
SN - 0895-4356
VL - 155
SP - 84
EP - 96
JO - Journal of Clinical Epidemiology
JF - Journal of Clinical Epidemiology
ER -